Ying Dai

ORCID: 0000-0003-4164-6505
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease Diagnosis and Treatment
  • Antibiotics Pharmacokinetics and Efficacy
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Antimicrobial Resistance in Staphylococcus
  • Antibiotic Resistance in Bacteria
  • Pharmacovigilance and Adverse Drug Reactions
  • Ultrasound and Hyperthermia Applications
  • Ovarian cancer diagnosis and treatment
  • Lung Cancer Treatments and Mutations
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • Higher Education and Teaching Methods
  • Neuroendocrine Tumor Research Advances
  • Cancer Mechanisms and Therapy
  • Tuberculosis Research and Epidemiology
  • Pancreatic function and diabetes
  • PARP inhibition in cancer therapy
  • Neurological Disorders and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Gallbladder and Bile Duct Disorders
  • Engineering Education and Curriculum Development
  • Drug-Induced Adverse Reactions
  • Regulation of Appetite and Obesity
  • Neuroinflammation and Neurodegeneration Mechanisms

Qiqihar Medical University
2025

Shandong First Medical University
2025

Shandong Provincial Hospital
2025

Wenzhou Medical University
2017-2024

First Affiliated Hospital of Wenzhou Medical University
2017-2024

Sichuan Academy of Traditional Chinese Medicine
2021-2024

Ningbo University
2024

Peking University
2006-2021

Peking University Cancer Hospital
2009-2021

First Affiliated Hospital of Anhui Medical University
2021

Current FDA-approved label recommends that the dosage of polymyxin B should be adjusted according to renal function. However, correlation between pharmacokinetics (PK) and creatinine clearance (CrCL) is poor. This study aimed develop a population PK model in adult patients with various functions identify dosing strategy.A retrospective was performed 32 Nonlinear mixed effects modelling applied build followed by Monte Carlo simulations which designed regimens across function.Polymyxin...

10.1111/bcp.14576 article EN British Journal of Clinical Pharmacology 2020-10-01

1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione (tetrahydrocurcumin, THC) is a major bioactive metabolite of curcumin, demonstrating the potential anti-inflammatory, antioxidant and neuroprotective properties, etc. In this study, it was found that Aβ induced decreased cell viability, cycle arrest apoptosis in BV-2 cells, which were ameliorated by THC. vivo, THC administration rescued learning memory, reduced burden hippocampus APP/PS1 mice. By proteomic analysis mice, 157 differentially...

10.1016/j.biopha.2021.111651 article EN Biomedicine & Pharmacotherapy 2021-05-08

Background: Presently, colistin is commercially available in two different forms, namely, sulfate and its sulphomethylated derivative, colistimethate sodium (CMS). However, the currently reported studies, most of clinical studies on for parenteral use are referred to as CMS. Data pharmacokinetics (PK), efficacy, side effects have not been reported. Methods: This retrospective study was performed carbapenem-resistant organism (CRO)-infected patients treated with more than 72 h. The population...

10.3389/fphar.2022.915958 article EN cc-by Frontiers in Pharmacology 2022-06-16

Chronic hepatitis B (CHB) patients receiving entecavir (ETV) treatment might develop low-level viremia (LLV), which is proven to be associated with worse clinical outcomes, such as risk of drug-related mutations, progression cirrhosis, and even hepatocellular carcinoma. This real-world prospective study evaluated the efficacy safety switching from ETV tenofovir alafenamide fumarate (TAF) in CHB LLV. From August 2020 2023, 351 ETV-experienced LLV were enrolled eight hospitals. Patients either...

10.1128/aac.01827-24 article EN cc-by Antimicrobial Agents and Chemotherapy 2025-02-04

To assess the efficacy and safety of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) in recurrent hepatocellular carcinoma (HCC) after hepatectomy to compare its outcome a single modality.We retrospectively studied 103 patients HCCs who were excluded from repeat hepatectomy. Of them, 81 male 22 female (mean age 55.8 +/- 10.7 years; range, 30-80 years). According treatment modality, these divided into three groups: RFA was used as sole first-line anticancer...

10.1111/j.1872-034x.2008.00451.x article EN Hepatology Research 2008-11-13

What is known and objectives Haematological toxicity including thrombocytopenia, anaemia leucopenia the main adverse events of linezolid (LZD) therapy. This study aimed to investigate risk factors for LZD-induced haematological define threshold plasma trough concentration minimize toxicity. Methods 145 patients who received LZD more than 10 days were retrospectively reviewed determine incidence Meanwhile, confirmed by univariate multivariate logistic regression analysis. Results discussion 9...

10.1111/jcpt.13359 article EN Journal of Clinical Pharmacy and Therapeutics 2021-02-08

Background: Linezolid is associated with myelosuppression, which may cause failure in optimally treating bacterial infections. The study aimed to define the pharmacokinetic/toxicodynamic (PK/TD) threshold for critically ill patients and identify a dosing strategy renal insufficiency. Methods: population pharmacokinetic (PK) model was developed using NONMEM program. Logistic regression modeling conducted determine toxicodynamic (TD) of linezolid-induced myelosuppression. regimen optimized...

10.3389/fphar.2022.844567 article EN cc-by Frontiers in Pharmacology 2022-04-11

To evaluate whether contrast-enhanced ultrasound (CEUS) with SonoVue could differentiate malignant focal liver lesions (FLLs) from benign and provide lesion type diagnoses.Four hundred fifty-six patients 554 FLLs were examined by CEUS using low mechanical index, nonlinear imaging techniques. Each was characterized 2 independent off-site readers as or given specific diagnosis, if possible, both at baseline (US) after administration (CEUS). The final diagnosis achieved histopathology obtained...

10.1097/rli.0b013e318050ab29 article EN Investigative Radiology 2007-07-09

To investigate the diagnostic value for diagnosis of small (1-2 cm) hepatic nodules detected by surveillance ultrasound in patients with cirrhosis using contrast-enhanced (CEUS) compared that helical computed tomography (CECT).Seventy-two liver 103 were enrolled present study. All underwent CEUS SonoVue as well CECT. Nodules which appeared contrast enhancement during arterial phase and wash-out late on or CECT diagnosed malignant (hepatocellular carcinoma [HCC]). Histopathology obtained from...

10.1111/j.1872-034x.2007.00269.x article EN Hepatology Research 2007-10-01

To determine the incidence, risk factors and prognosis associated with needle track seeding after percutaneous radiofrequency ablations (RFA) for hepatocellular carcinoma (HCC) a long-term follow-up.A total of 741 HCC patients undergoing RFA were retrospectively analysed. Mean follow-up interval was 34.3 ± 26.8 months. All neoplasms diagnosed by imaging modalities or without pathological evaluation. Risk factors, including Child-Pugh grading, tumour size, number, location, serum...

10.1080/02656736.2017.1278630 article EN International Journal of Hyperthermia 2017-01-04

Aims Data regarding clinical pharmacokinetic/toxicodynamic (PK/TD) of polymyxin B is short direct quantitative data. This study aims to investigate the risk factors associated acute kidney injury (AKI) and assess relationship between plasma levels its nephrotoxicity. Methods A retrospective was performed in adult patients treated with B. Risk AKI trough concentrations were identified via medical record review. multivariate logistic regression model established B‐associated predicted by a...

10.1111/bcp.15061 article EN British Journal of Clinical Pharmacology 2021-08-27

This study aimed to investigate the diagnostic value of contrast-enhanced ultrasound (CEUS) small hepatocellular carcinomas (HCC) (</=3cm) in patient with cirrhosis.Fifty-seven cases 64 HCC tumors were analyzed this study. In these cases, all patients had liver cirrhosis and surgical or biopsy histopathological diagnosis. Diagnosis baseline (US) CEUS each lesion was made separately using a 5-point scoring system based on US characteristics lesions compared results.All 47 moderately poorly...

10.1016/j.hepres.2006.04.013 article EN Hepatology Research 2006-06-20

Background: Sirolimus is a promising immunosuppressive drug for preventing the rejection of organ transplants. However, inter-individual variability in sirolimus pharmacokinetics causes adverse reactions, compromising therapeutic efficacy. primarily metabolized by cytochrome CYP3A4 and CYP3A5. This study aimed to clarify effect CYP3A genetic polymorphisms, including CYP3A4*1G CYP3A5*3 on sirolimus. Methods: Thirty-one healthy Chinese volunteers were included this study. Their genotypes...

10.1097/ftd.0000000000000415 article EN Therapeutic Drug Monitoring 2017-07-12

What is known and objective Lactic acidosis (LA) a rare but potentially lethal side effect of linezolid (LZD). However, limited by the study population, number patients with LA insufficient to summarize all clinical characteristics risk factors. Methods We evaluated association between LZD using reporting odd ratio (ROR) for mining adverse event report signals in FDA Adverse Event Reporting System database from January 2013 December 2019. Results discussion There were 6218 reports as primary...

10.1111/jcpt.13245 article EN Journal of Clinical Pharmacy and Therapeutics 2020-08-09

The purpose of this study was to evaluate the use contrast-enhanced ultrasonography (CEUS) in selecting patients with hepatocellular carcinoma (HCC) for radio frequency ablation (RFA).One hundred seventy-nine HCC were divided into 2 groups before receiving RFA: a CEUS group and control group. concatenated alternately apportioned these groups. In group, 92 underwent pre-RFA using contrast agent sulfur hexafluoride enhanced computed tomography or magnetic resonance imaging RFA suitable cases...

10.7863/jum.2007.26.8.1055 article EN Journal of Ultrasound in Medicine 2007-08-01
Coming Soon ...